Number of Drugs under Consideration by pCPA, 3-month quarterly Average, Q1 2019 – Q2 2023

Bar chart. Vertical axis labeled "Number of Drugs" ranging from 0 to 45.

Year	Quarter	Number of Drugs
2019	Q1	12
2019	Q2	13
2019	Q3	11
2019	Q4	6
2020	Q1	11
2020	Q2	21
2020	Q3	21
2020	Q4	25
2021	Q1	28
2021	Q2	28
2021	Q3	29
2021	Q4	25
2022	Q1	27
2022	Q2	30
2022	Q3	31
2022	Q4	37
2023	Q1	39
2023	Q2	33

* Does not include drugs where negotiations were not pursued or subsequent pCPA attempts after the first attempt

Source: IMC analysis of pCPA data collected from https://www.pcpacanada.ca/negotiations and CADTH data collected from https://cadth.ca/reimbursement-review-reports.

Number of new pCPA Negotiations

Source: IMC analysis of pCPA data collected from https://www.pcpacanada.ca/negotiations and CADTH data collected from https://cadth.ca/reimbursement-review-reports.

CADTH Recommendation to pCPA Engagement, All Drugs

Chart — horizontal bar chart titled "CADTH Recommendation to pCPA Engagement, All Drugs"

Y-axis: Date of pCPA LOI
X-axis: Days from CADTH Recommendation to pCPA Engagement

Date of pCPA LOI	Days
2019	115
2020	90
2021	123
2022	159
2023	166

* Does not include drugs where negotiations were not pursued or subsequent pCPA attempts after the first attempt

Source: IMC analysis of pCPA data collected from https://www.pcpacanada.ca/negotiations and CADTH data collected from https://cadth.ca/reimbursement-review-reports.

Number of Active pCPA Negotiations, 3-month Quarterly Average, Q1 2019 – Q2 2023

Q1	Q2	Q3	Q4		Q1	Q2	Q3	Q4		Q1	Q2	Q3	Q4		Q1	Q2	Q3	Q4		Q1	Q2
45	45	48	42		33	25	29	29		32	33	40	37		40	41	34	32		38	34
2019					**2020**					**2021**					**2022**					**2023**	

Source: IMC analysis of pCPA data collected from https://www.pcpacanada.ca/negotiations.

Number of Active pCPA Negotiations and Files Under Consideration, 3-month Quarterly Average, Q1 2019 – Q2 2023

Legend: Active Negotiations (dark blue), Under Consideration (light blue)

Y-axis: Number of Drugs

	2019				2020				2021				2022				2023	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Total	57	58	59	48	44	46	50	54	60	61	69	62	67	71	65	69	77	67
Under Consideration	12	13	11	6	11	21	21	25	28	28	29	25	27	30	31	37	39	33
Active Negotiations	45	45	48	42	33	25	29	29	32	33	40	37	40	41	34	32	38	34

Source: IMC analysis of pCPA data collected from https://www.pcpacanada.ca/negotiations.

pCPA Total Time, All Drugs

Target Timeline 180 days

Date of pCPA LOI

2020 (N=48): 317
2021 (N=62): 277
2022 (N=66): 321
2023 Q2 (N=49): 301

Days from CADTH Recommendation

(x-axis: 50, 100, 150, 200, 250, 300, 350)

N = number of completed negotiations

Source: IMC analysis of pCPA data collected from https://www.pcpacanada.ca/negotiations.

Negotiations on BPG target

23%
21%
22%
26%*

**BPG – Brand Process Guidelines**

* 4 of the negotiations concluded <180 days in 2023 Q1 were new indications of an existing product, with 0 days from LOE to LOI

pCPA Total Time, All Drugs

Target Timeline
180 days

Date of pCPA LOI	Days from CADTH Recommendation
2021	277 days
2022	321 days
2023 Q2	301 days

Days from CADTH Recommendation

50   100   150   200   250   300   350

Negotiations on Brand Process Guidelines Target

2021
21%

2022
22%

2023
26%*

* 4 of the negotiations concluded <180 days in 2023 Q1 were new indica-
tions of an existing product, with 0 days from LOE to LOI

Source: IMC analysis of pCPA data collected from https://www.pcpacanada.ca/negotiations.